login
Password reminder
Cardiac Rhythm News
Contact the editor Visit Cardiac Rhythm News Twitter feed Visit Cardiac Rhythm News Facebook page
 

Novel imaging technique may predict outcomes in AF patients


Thursday, 09 Apr 2009 09:03

University of Utah researchers have found that delayed-enhancement magnetic resonance imaging (DE-MRI) holds promise for predicting treatment outcomes and measuring disease progression for patients with atrial fibrillation (AF). Their latest study on a novel application of this technology for atrial fibrillation appears in the 7 April issue of the journal Circulation.


Although DE-MRI is an established method for visualising tissue damage in cardiac disease processes, the study assessed its use in a protocol developed to detect fibrosis in atrial fibrillation patients before they underwent radiofrequency ablation. This procedure involves the use of catheters that emit mild, painless radiofrequency energy to destroy carefully selected heart muscle cells to stop them from conducting extra electrical impulses.


In this study, the University of Utah colleagues developed a protocol using DE-CMRI to create 3D images of the left atrium before radiofrequency ablation, which were processed and analysed with custom software tools and computer algorithms to calculate the extent of left atrium wall injury. Patients were then assessed at least six months after the procedure, and the researchers found that only 14% classified as having minimal fibrosis had suffered atrial fibrillation recurrence compared to 75% recurrence for the group that had extensive scar tissue damage.


"Our results indicate that DE-MRI provides a noninvasive means of assessing left atrial myocardial tissue in patients suffering from atrial fibrillation, and that those who do have tissue damage may be at greater risk of suffering AF recurrence after treatment with radiofrequency ablation," said lead author Dr Nassir F Marrouche, University of Utah School of Medicine and director of the Atrial Fibrillation Program. "Our findings also present a disease progression model that supports the importance of early intervention."


In addition to its noninvasive nature, DE-MRI offers other advantages over commonly used invasive electroanatomic mapping studies to assess tissue health. For example, while other such diagnostic mapping studies have been associated with a high degree of spatial error, three-dimensional DE-MRI provides information on both the anatomy and the location of pathology without spatial distortion. Marrouche and his colleagues also have developed methods of processing the MRI images in order to visualise the entire volume of left atrium wall injury in 3D.


"Until now, there has not been an accurate, noninvasive way to assess left atrium scar formation, which studies show is linked to AF disease severity," said Marrouche. "If substantiated, our DE-MRI visualisation technique and analysis would provide guidance in determining appropriate candidates for AF catheter ablation as well as in identifying the heart muscle cells that need to be destroyed."


Last fall, the University of Utah Atrial Fibrillation program became the first in the world to be able to ablate using a catheter custom-made to be compatible with MRI. Next month, University Health Care will open a new multimillion dollar clinical and research lab, which will be the first in North America to provide real-time DE-MRI for treating patients with AF.




Add New Comment

Most popular


Abbott to acquire St Jude Medical
Tuesday, 03 May 2016
Abbott is set to acquire St Jude Medical, expanding its portfolio to cover cardiovascular markets such as atrial fibrillation, structural heart and heart failure as well as neuromodulation. The ... Abbott to acquire St Jude Medical

First leadless pacemaker approved in the USA
Wednesday, 06 Apr 2016
Medtronic has announced it has received US Food and Drug Administration (FDA) approval for its Micra Transcatheter Pacing System (TPS). The leadless device, which is 93% smaller than conventional ... First leadless pacemaker approved in the USA

Presence of a wide and large S-wave in lead I is a powerful predictor of life-threatening ventricular arrhythmias in Brugada Syndrome patients
Wednesday, 30 Mar 2016
New research published in the Journal of the American College of Cardiology indicates that a wide/and or large S-wave in lead I is a powerful predictor of life-threatening ventricular arrhythmias in B... Presence of a wide and large S-wave in lead I is a powerful predictor of life-threatening ventricular arrhythmias in Brugada Syndrome patients

Features


Importance of obstructive sleep apnoea in EP
Thursday, 26 May 2016
Syed Rafay A Sabzwari and Dhanunjaya Lakkireddy (Kansas City, USA) review the importance of obstructive sleep apnoea (OSA) in electrophysiology and cardiology at large, as a secondary impact to an ... Importance of obstructive sleep apnoea in EP

Ventricular tachycardia ablation in Chagas disease
Friday, 13 May 2016
Guilherme Fenelon (Sao Paulo, Brazil) overviews the role of ablation of ventricular tachycardia in Chagas disease. He says: catheter ablation in Chagas disease remains a “challenging procedure,” ... Ventricular tachycardia ablation in Chagas disease

Profiles


George Van Hare
Wednesday, 04 May 2016
George Van Hare (The Louis Larrick Ward professor of Pediatrics and director, Division of Pediatric ... George Van Hare

Jonathan Kalman
Monday, 18 Jan 2016
A leading heart rhythm expert in Australia, Jonathan M Kalman directs both clinical and research ... Jonathan Kalman

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions